key: cord-0819012-bnm8o82q authors: Caroppo, Francesca; Deotto, Maria Ludovica; Tartaglia, Jacopo; Belloni Fortina, Anna title: Vitiligo worsened following the second dose of mRNA SARS‐CoV‐2 vaccine date: 2022-03-16 journal: Dermatol Ther DOI: 10.1111/dth.15434 sha: b35b297cff554316cc146a65ef7ac2266aa7fa19 doc_id: 819012 cord_uid: bnm8o82q nan The pathophysiology underlying the relationship between SARS-CoV-2 vaccination and vitiligo remains unclear, but several F I G U R E 1 Worsening of vitiligo following the second dose of mRNA SARS-CoV-2 vaccination. Clinical examination showed extended vitiligo lesions involving extremities, upper limbs, axillae, trunk, and genital area with large confluent lesions. The extent of hypopigmentation was estimated at about 70% of the patient's body surface area Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID-19 vaccine Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence? Vitiligo possibly triggered by COVID-19 vaccination New-onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination Sudden onset of vitiligo after COVID-19 vaccine A new-onset vitiligo following the inactivated COVID-19 vaccine COVID vaccine-induced lichen planus on areas previously affected by vitiligo Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? Comment on 'Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence? Type I interferons as possible link between COVID-19 vaccine and vitiligo SARS-CoV-2 induces human plasmacytoid pre-dendritic cell diversification via UNC93B and IRAK4 Type I interferon signature in the initiation of the immune response in vitiligo